332 related articles for article (PubMed ID: 32030759)
1. In situ antitumor vaccination: Targeting the tumor microenvironment.
Li H; Yu J; Wu Y; Shao B; Wei X
J Cell Physiol; 2020 Jul; 235(7-8):5490-5500. PubMed ID: 32030759
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
3. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
4. In situ vaccination for the treatment of cancer.
Hammerich L; Bhardwaj N; Kohrt HE; Brody JD
Immunotherapy; 2016; 8(3):315-30. PubMed ID: 26860335
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
6. Role of Local Radiation Therapy in Cancer Immunotherapy.
Demaria S; Golden EB; Formenti SC
JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.
Locy H; de Mey S; de Mey W; De Ridder M; Thielemans K; Maenhout SK
Front Immunol; 2018; 9():2909. PubMed ID: 30619273
[TBL] [Abstract][Full Text] [Related]
8. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
9. Recombinant
Deng W; Lira V; Hudson TE; Lemmens EE; Hanson WG; Flores R; Barajas G; Katibah GE; Desbien AL; Lauer P; Leong ML; Portnoy DA; Dubensky TW
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8179-8184. PubMed ID: 30038013
[TBL] [Abstract][Full Text] [Related]
10. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
11. CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Diken M; Boegel S; Grunwitz C; Kranz LM; Reuter K; van de Roemer N; Vascotto F; Vormehr M; Kreiter S
Hum Vaccin Immunother; 2014; 10(10):3090-100. PubMed ID: 25483671
[No Abstract] [Full Text] [Related]
12. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
13. Methods for improving the immunogenicity and efficacy of cancer vaccines.
Pilla L; Ferrone S; Maccalli C
Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
[TBL] [Abstract][Full Text] [Related]
14. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K; Bialkowski L; Daszkiewicz L; Broos K; Goyvaerts C; Renmans D; Van Lint S; Heirman C; Thielemans K; Breckpot K
Oncotarget; 2015 Jan; 6(3):1359-81. PubMed ID: 25682197
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A
Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
18. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
19. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Fecek RJ; Storkus WJ
Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor-associated macrophages to synergize tumor immunotherapy.
Xiang X; Wang J; Lu D; Xu X
Signal Transduct Target Ther; 2021 Feb; 6(1):75. PubMed ID: 33619259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
